Global Down Syndrome Market by Disease Type (Trisomy 21, Mosaic Down Syndrome, Translocation Down Syndrome), by End User (Research Institutes, Hospitals), by Treatment (Diagnosis, Therapy) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Down Syndrome Market research report which is segmented by Disease Type (Trisomy 21, Mosaic Down Syndrome, Translocation Down Syndrome), by End User (Research Institutes, Hospitals), by Treatment (Diagnosis, Therapy), By Players/Companies Novo Nordisk AS, Pfizer Inc., Kyowa Kirin Co. Ltd., Bayer AG, Shire Inc., Novartis Pharmaceuticals Corporation, Bluebird Bio Inc., CSL Limited, GlaxoSmithKline Plc., Octapharma AG, Jiangsu Hengrui Medicine Co. Ltd., Amgen Inc.”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Down Syndrome Market Research Report |
| By Disease Type | Trisomy 21, Mosaic Down Syndrome, Translocation Down Syndrome |
| By End User | Research Institutes, Hospitals |
| By Treatment | Diagnosis, Therapy |
| By Companies | Novo Nordisk AS, Pfizer Inc., Kyowa Kirin Co. Ltd., Bayer AG, Shire Inc., Novartis Pharmaceuticals Corporation, Bluebird Bio Inc., CSL Limited, GlaxoSmithKline Plc., Octapharma AG, Jiangsu Hengrui Medicine Co. Ltd., Amgen Inc. |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 243 |
| Number of Tables & Figures | 171 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Down Syndrome Market Report Segments:
The market is segmented by Disease Type (Trisomy 21, Mosaic Down Syndrome, Translocation Down Syndrome), by End User (Research Institutes, Hospitals), by Treatment (Diagnosis, Therapy).
Some of the companies that are profiled in this report are:
- Novo Nordisk AS
- Pfizer Inc.
- Kyowa Kirin Co. Ltd.
- Bayer AG
- Shire Inc.
- Novartis Pharmaceuticals Corporation
- Bluebird Bio Inc.
- CSL Limited
- GlaxoSmithKline Plc.
- Octapharma AG
- Jiangsu Hengrui Medicine Co. Ltd.
- Amgen Inc.
Down Syndrome Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Down Syndrome Market
Overview of the regional outlook of the Down Syndrome Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Down Syndrome Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Down Syndrome Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Trisomy 21
2. Mosaic Down Syndrome
3. Translocation Down Syndrome
7. By End User:1. Research Institutes
2. Hospitals
8. By Treatment:1. Diagnosis
2. Therapy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Down Syndrome Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Down Syndrome Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Down Syndrome Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Down Syndrome Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Down Syndrome Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Down Syndrome Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Down Syndrome Market Size & Forecast, 2018-2028
4.5.1 Down Syndrome Market Size and Y-o-Y Growth
4.5.2 Down Syndrome Market Absolute $ Opportunity
Chapter 5 Global Down Syndrome Market Analysis and Forecast by Disease Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Disease Type
5.1.2 Basis Point Share (BPS) Analysis by Disease Type
5.1.3 Absolute $ Opportunity Assessment by Disease Type
5.2 Down Syndrome Market Size Forecast by Disease Type
5.2.1 Trisomy 21
5.2.2 Mosaic Down Syndrome
5.2.3 Translocation Down Syndrome
5.3 Market Attractiveness Analysis by Disease Type
Chapter 6 Global Down Syndrome Market Analysis and Forecast by End User
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by End User
6.1.2 Basis Point Share (BPS) Analysis by End User
6.1.3 Absolute $ Opportunity Assessment by End User
6.2 Down Syndrome Market Size Forecast by End User
6.2.1 Research Institutes
6.2.2 Hospitals
6.3 Market Attractiveness Analysis by End User
Chapter 7 Global Down Syndrome Market Analysis and Forecast by Treatment
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Treatment
7.1.2 Basis Point Share (BPS) Analysis by Treatment
7.1.3 Absolute $ Opportunity Assessment by Treatment
7.2 Down Syndrome Market Size Forecast by Treatment
7.2.1 Diagnosis
7.2.2 Therapy
7.3 Market Attractiveness Analysis by Treatment
Chapter 8 Global Down Syndrome Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Down Syndrome Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Down Syndrome Analysis and Forecast
10.1 Introduction
10.2 North America Down Syndrome Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Down Syndrome Market Size Forecast by Disease Type
10.6.1 Trisomy 21
10.6.2 Mosaic Down Syndrome
10.6.3 Translocation Down Syndrome
10.7 Basis Point Share (BPS) Analysis by Disease Type
10.8 Absolute $ Opportunity Assessment by Disease Type
10.9 Market Attractiveness Analysis by Disease Type
10.10 North America Down Syndrome Market Size Forecast by End User
10.10.1 Research Institutes
10.10.2 Hospitals
10.11 Basis Point Share (BPS) Analysis by End User
10.12 Absolute $ Opportunity Assessment by End User
10.13 Market Attractiveness Analysis by End User
10.14 North America Down Syndrome Market Size Forecast by Treatment
10.14.1 Diagnosis
10.14.2 Therapy
10.15 Basis Point Share (BPS) Analysis by Treatment
10.16 Absolute $ Opportunity Assessment by Treatment
10.17 Market Attractiveness Analysis by Treatment
Chapter 11 Europe Down Syndrome Analysis and Forecast
11.1 Introduction
11.2 Europe Down Syndrome Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Down Syndrome Market Size Forecast by Disease Type
11.6.1 Trisomy 21
11.6.2 Mosaic Down Syndrome
11.6.3 Translocation Down Syndrome
11.7 Basis Point Share (BPS) Analysis by Disease Type
11.8 Absolute $ Opportunity Assessment by Disease Type
11.9 Market Attractiveness Analysis by Disease Type
11.10 Europe Down Syndrome Market Size Forecast by End User
11.10.1 Research Institutes
11.10.2 Hospitals
11.11 Basis Point Share (BPS) Analysis by End User
11.12 Absolute $ Opportunity Assessment by End User
11.13 Market Attractiveness Analysis by End User
11.14 Europe Down Syndrome Market Size Forecast by Treatment
11.14.1 Diagnosis
11.14.2 Therapy
11.15 Basis Point Share (BPS) Analysis by Treatment
11.16 Absolute $ Opportunity Assessment by Treatment
11.17 Market Attractiveness Analysis by Treatment
Chapter 12 Asia Pacific Down Syndrome Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Down Syndrome Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Down Syndrome Market Size Forecast by Disease Type
12.6.1 Trisomy 21
12.6.2 Mosaic Down Syndrome
12.6.3 Translocation Down Syndrome
12.7 Basis Point Share (BPS) Analysis by Disease Type
12.8 Absolute $ Opportunity Assessment by Disease Type
12.9 Market Attractiveness Analysis by Disease Type
12.10 Asia Pacific Down Syndrome Market Size Forecast by End User
12.10.1 Research Institutes
12.10.2 Hospitals
12.11 Basis Point Share (BPS) Analysis by End User
12.12 Absolute $ Opportunity Assessment by End User
12.13 Market Attractiveness Analysis by End User
12.14 Asia Pacific Down Syndrome Market Size Forecast by Treatment
12.14.1 Diagnosis
12.14.2 Therapy
12.15 Basis Point Share (BPS) Analysis by Treatment
12.16 Absolute $ Opportunity Assessment by Treatment
12.17 Market Attractiveness Analysis by Treatment
Chapter 13 Latin America Down Syndrome Analysis and Forecast
13.1 Introduction
13.2 Latin America Down Syndrome Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Down Syndrome Market Size Forecast by Disease Type
13.6.1 Trisomy 21
13.6.2 Mosaic Down Syndrome
13.6.3 Translocation Down Syndrome
13.7 Basis Point Share (BPS) Analysis by Disease Type
13.8 Absolute $ Opportunity Assessment by Disease Type
13.9 Market Attractiveness Analysis by Disease Type
13.10 Latin America Down Syndrome Market Size Forecast by End User
13.10.1 Research Institutes
13.10.2 Hospitals
13.11 Basis Point Share (BPS) Analysis by End User
13.12 Absolute $ Opportunity Assessment by End User
13.13 Market Attractiveness Analysis by End User
13.14 Latin America Down Syndrome Market Size Forecast by Treatment
13.14.1 Diagnosis
13.14.2 Therapy
13.15 Basis Point Share (BPS) Analysis by Treatment
13.16 Absolute $ Opportunity Assessment by Treatment
13.17 Market Attractiveness Analysis by Treatment
Chapter 14 Middle East & Africa (MEA) Down Syndrome Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Down Syndrome Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Down Syndrome Market Size Forecast by Disease Type
14.6.1 Trisomy 21
14.6.2 Mosaic Down Syndrome
14.6.3 Translocation Down Syndrome
14.7 Basis Point Share (BPS) Analysis by Disease Type
14.8 Absolute $ Opportunity Assessment by Disease Type
14.9 Market Attractiveness Analysis by Disease Type
14.10 Middle East & Africa (MEA) Down Syndrome Market Size Forecast by End User
14.10.1 Research Institutes
14.10.2 Hospitals
14.11 Basis Point Share (BPS) Analysis by End User
14.12 Absolute $ Opportunity Assessment by End User
14.13 Market Attractiveness Analysis by End User
14.14 Middle East & Africa (MEA) Down Syndrome Market Size Forecast by Treatment
14.14.1 Diagnosis
14.14.2 Therapy
14.15 Basis Point Share (BPS) Analysis by Treatment
14.16 Absolute $ Opportunity Assessment by Treatment
14.17 Market Attractiveness Analysis by Treatment
Chapter 15 Competition Landscape
15.1 Down Syndrome Market: Competitive Dashboard
15.2 Global Down Syndrome Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Novo Nordisk AS
15.3.2 Pfizer Inc.
15.3.3 Kyowa Kirin Co. Ltd.
15.3.4 Bayer AG
15.3.5 Shire Inc.
15.3.6 Novartis Pharmaceuticals Corporation
15.3.7 Bluebird Bio Inc.
15.3.8 CSL Limited
15.3.9 GlaxoSmithKline Plc.
15.3.10 Octapharma AG
15.3.11 Jiangsu Hengrui Medicine Co. Ltd.
15.3.12 Amgen Inc.
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Down Syndrome Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Down Syndrome Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Down Syndrome Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Down Syndrome Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Down Syndrome Market Size & Forecast, 2018-2028
4.5.1 Down Syndrome Market Size and Y-o-Y Growth
4.5.2 Down Syndrome Market Absolute $ Opportunity
Chapter 5 Global Down Syndrome Market Analysis and Forecast by Disease Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Disease Type
5.1.2 Basis Point Share (BPS) Analysis by Disease Type
5.1.3 Absolute $ Opportunity Assessment by Disease Type
5.2 Down Syndrome Market Size Forecast by Disease Type
5.2.1 Trisomy 21
5.2.2 Mosaic Down Syndrome
5.2.3 Translocation Down Syndrome
5.3 Market Attractiveness Analysis by Disease Type
Chapter 6 Global Down Syndrome Market Analysis and Forecast by End User
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by End User
6.1.2 Basis Point Share (BPS) Analysis by End User
6.1.3 Absolute $ Opportunity Assessment by End User
6.2 Down Syndrome Market Size Forecast by End User
6.2.1 Research Institutes
6.2.2 Hospitals
6.3 Market Attractiveness Analysis by End User
Chapter 7 Global Down Syndrome Market Analysis and Forecast by Treatment
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Treatment
7.1.2 Basis Point Share (BPS) Analysis by Treatment
7.1.3 Absolute $ Opportunity Assessment by Treatment
7.2 Down Syndrome Market Size Forecast by Treatment
7.2.1 Diagnosis
7.2.2 Therapy
7.3 Market Attractiveness Analysis by Treatment
Chapter 8 Global Down Syndrome Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Down Syndrome Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Down Syndrome Analysis and Forecast
10.1 Introduction
10.2 North America Down Syndrome Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Down Syndrome Market Size Forecast by Disease Type
10.6.1 Trisomy 21
10.6.2 Mosaic Down Syndrome
10.6.3 Translocation Down Syndrome
10.7 Basis Point Share (BPS) Analysis by Disease Type
10.8 Absolute $ Opportunity Assessment by Disease Type
10.9 Market Attractiveness Analysis by Disease Type
10.10 North America Down Syndrome Market Size Forecast by End User
10.10.1 Research Institutes
10.10.2 Hospitals
10.11 Basis Point Share (BPS) Analysis by End User
10.12 Absolute $ Opportunity Assessment by End User
10.13 Market Attractiveness Analysis by End User
10.14 North America Down Syndrome Market Size Forecast by Treatment
10.14.1 Diagnosis
10.14.2 Therapy
10.15 Basis Point Share (BPS) Analysis by Treatment
10.16 Absolute $ Opportunity Assessment by Treatment
10.17 Market Attractiveness Analysis by Treatment
Chapter 11 Europe Down Syndrome Analysis and Forecast
11.1 Introduction
11.2 Europe Down Syndrome Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Down Syndrome Market Size Forecast by Disease Type
11.6.1 Trisomy 21
11.6.2 Mosaic Down Syndrome
11.6.3 Translocation Down Syndrome
11.7 Basis Point Share (BPS) Analysis by Disease Type
11.8 Absolute $ Opportunity Assessment by Disease Type
11.9 Market Attractiveness Analysis by Disease Type
11.10 Europe Down Syndrome Market Size Forecast by End User
11.10.1 Research Institutes
11.10.2 Hospitals
11.11 Basis Point Share (BPS) Analysis by End User
11.12 Absolute $ Opportunity Assessment by End User
11.13 Market Attractiveness Analysis by End User
11.14 Europe Down Syndrome Market Size Forecast by Treatment
11.14.1 Diagnosis
11.14.2 Therapy
11.15 Basis Point Share (BPS) Analysis by Treatment
11.16 Absolute $ Opportunity Assessment by Treatment
11.17 Market Attractiveness Analysis by Treatment
Chapter 12 Asia Pacific Down Syndrome Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Down Syndrome Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Down Syndrome Market Size Forecast by Disease Type
12.6.1 Trisomy 21
12.6.2 Mosaic Down Syndrome
12.6.3 Translocation Down Syndrome
12.7 Basis Point Share (BPS) Analysis by Disease Type
12.8 Absolute $ Opportunity Assessment by Disease Type
12.9 Market Attractiveness Analysis by Disease Type
12.10 Asia Pacific Down Syndrome Market Size Forecast by End User
12.10.1 Research Institutes
12.10.2 Hospitals
12.11 Basis Point Share (BPS) Analysis by End User
12.12 Absolute $ Opportunity Assessment by End User
12.13 Market Attractiveness Analysis by End User
12.14 Asia Pacific Down Syndrome Market Size Forecast by Treatment
12.14.1 Diagnosis
12.14.2 Therapy
12.15 Basis Point Share (BPS) Analysis by Treatment
12.16 Absolute $ Opportunity Assessment by Treatment
12.17 Market Attractiveness Analysis by Treatment
Chapter 13 Latin America Down Syndrome Analysis and Forecast
13.1 Introduction
13.2 Latin America Down Syndrome Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Down Syndrome Market Size Forecast by Disease Type
13.6.1 Trisomy 21
13.6.2 Mosaic Down Syndrome
13.6.3 Translocation Down Syndrome
13.7 Basis Point Share (BPS) Analysis by Disease Type
13.8 Absolute $ Opportunity Assessment by Disease Type
13.9 Market Attractiveness Analysis by Disease Type
13.10 Latin America Down Syndrome Market Size Forecast by End User
13.10.1 Research Institutes
13.10.2 Hospitals
13.11 Basis Point Share (BPS) Analysis by End User
13.12 Absolute $ Opportunity Assessment by End User
13.13 Market Attractiveness Analysis by End User
13.14 Latin America Down Syndrome Market Size Forecast by Treatment
13.14.1 Diagnosis
13.14.2 Therapy
13.15 Basis Point Share (BPS) Analysis by Treatment
13.16 Absolute $ Opportunity Assessment by Treatment
13.17 Market Attractiveness Analysis by Treatment
Chapter 14 Middle East & Africa (MEA) Down Syndrome Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Down Syndrome Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Down Syndrome Market Size Forecast by Disease Type
14.6.1 Trisomy 21
14.6.2 Mosaic Down Syndrome
14.6.3 Translocation Down Syndrome
14.7 Basis Point Share (BPS) Analysis by Disease Type
14.8 Absolute $ Opportunity Assessment by Disease Type
14.9 Market Attractiveness Analysis by Disease Type
14.10 Middle East & Africa (MEA) Down Syndrome Market Size Forecast by End User
14.10.1 Research Institutes
14.10.2 Hospitals
14.11 Basis Point Share (BPS) Analysis by End User
14.12 Absolute $ Opportunity Assessment by End User
14.13 Market Attractiveness Analysis by End User
14.14 Middle East & Africa (MEA) Down Syndrome Market Size Forecast by Treatment
14.14.1 Diagnosis
14.14.2 Therapy
14.15 Basis Point Share (BPS) Analysis by Treatment
14.16 Absolute $ Opportunity Assessment by Treatment
14.17 Market Attractiveness Analysis by Treatment
Chapter 15 Competition Landscape
15.1 Down Syndrome Market: Competitive Dashboard
15.2 Global Down Syndrome Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Novo Nordisk AS
15.3.2 Pfizer Inc.
15.3.3 Kyowa Kirin Co. Ltd.
15.3.4 Bayer AG
15.3.5 Shire Inc.
15.3.6 Novartis Pharmaceuticals Corporation
15.3.7 Bluebird Bio Inc.
15.3.8 CSL Limited
15.3.9 GlaxoSmithKline Plc.
15.3.10 Octapharma AG
15.3.11 Jiangsu Hengrui Medicine Co. Ltd.
15.3.12 Amgen Inc.
Segments Covered in the Report
The global Down Syndrome market has been segmented based on
By Disease Type
The global Down Syndrome market has been segmented based on
By Disease Type
- Trisomy 21
- Mosaic Down Syndrome
- Translocation Down Syndrome
- Research Institutes
- Hospitals
- Diagnosis
- Therapy
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Novo Nordisk AS
- Pfizer Inc.
- Kyowa Kirin Co. Ltd.
- Bayer AG
- Shire Inc.
- Novartis Pharmaceuticals Corporation
- Bluebird Bio Inc.
- CSL Limited
- GlaxoSmithKline Plc.
- Octapharma AG
- Jiangsu Hengrui Medicine Co. Ltd.
- Amgen Inc.
Our Clients
Related Reports
Some other reports from this category!
